DE3023588C2 - Verwendung von Clonidin oder dessen Hydrochlorid zusammen mit Phentermin zum Abgewöhnen des Rauchens - Google Patents
Verwendung von Clonidin oder dessen Hydrochlorid zusammen mit Phentermin zum Abgewöhnen des RauchensInfo
- Publication number
- DE3023588C2 DE3023588C2 DE3023588A DE3023588A DE3023588C2 DE 3023588 C2 DE3023588 C2 DE 3023588C2 DE 3023588 A DE3023588 A DE 3023588A DE 3023588 A DE3023588 A DE 3023588A DE 3023588 C2 DE3023588 C2 DE 3023588C2
- Authority
- DE
- Germany
- Prior art keywords
- smoking
- nicotine
- phentermine
- hydrochloride
- clonidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000391 smoking effect Effects 0.000 title claims description 29
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 title claims description 24
- 229960003562 phentermine Drugs 0.000 title claims description 10
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 title claims description 7
- 229960002896 clonidine Drugs 0.000 title claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 20
- 229960002715 nicotine Drugs 0.000 description 20
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 20
- 235000019504 cigarettes Nutrition 0.000 description 17
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 13
- 241000208125 Nicotiana Species 0.000 description 12
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 12
- 229960002925 clonidine hydrochloride Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 206010048010 Withdrawal syndrome Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000779 smoke Substances 0.000 description 7
- 230000002889 sympathetic effect Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 239000002830 appetite depressant Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 150000002462 imidazolines Chemical class 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000019506 cigar Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 210000000192 parasympathetic ganglia Anatomy 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003639 vasoconstrictive effect Effects 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229940063628 catapres Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003455 ganglion stimulating agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940036543 ionamin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZEMQBDFHXOOXLY-UHFFFAOYSA-N ortetamine Chemical compound CC(N)CC1=CC=CC=C1C ZEMQBDFHXOOXLY-UHFFFAOYSA-N 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/057,288 US4255439A (en) | 1979-07-13 | 1979-07-13 | Means and method for aiding individuals to stop smoking |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3023588A1 DE3023588A1 (de) | 1981-01-29 |
| DE3023588C2 true DE3023588C2 (de) | 1996-01-25 |
Family
ID=22009680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3023588A Expired - Fee Related DE3023588C2 (de) | 1979-07-13 | 1980-06-24 | Verwendung von Clonidin oder dessen Hydrochlorid zusammen mit Phentermin zum Abgewöhnen des Rauchens |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4255439A (index.php) |
| JP (1) | JPS5618921A (index.php) |
| CA (1) | CA1152003A (index.php) |
| DE (1) | DE3023588C2 (index.php) |
| FR (1) | FR2460670A1 (index.php) |
| GB (1) | GB2056277B (index.php) |
| IT (1) | IT1149239B (index.php) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588739A (en) * | 1984-03-02 | 1986-05-13 | Research Foundation For Mental Hygiene, Inc. | Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking |
| US5096916A (en) * | 1990-05-07 | 1992-03-17 | Aegis Technology, Inc. | Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline |
| US5250286A (en) * | 1990-05-07 | 1993-10-05 | Aegis Technology, Inc. | Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline |
| US5271737A (en) * | 1992-09-04 | 1993-12-21 | U.S. Medical Products, Inc. | Tibial prosthetic implant with offset stem |
| AU6410394A (en) * | 1993-03-17 | 1994-10-11 | Pietr Hitzig | Method of treating addictive behaviors |
| US5336680A (en) * | 1993-05-18 | 1994-08-09 | Nietupski Ronald S | Smoking suppressant and method of application thereof |
| JP2601662Y2 (ja) * | 1993-08-24 | 1999-11-29 | 株式会社ニコン | フラッシュ装置装着可能なグリップ付きブラケット |
| US5527788A (en) * | 1994-01-18 | 1996-06-18 | Louisiana State Univ. Medical Center Foundation | Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
| US5502080A (en) * | 1994-11-01 | 1996-03-26 | Hitzig; Pietr | Combined use of dopamine and serotonin agonists in the treatment of allergic disorders |
| US5592956A (en) * | 1995-07-03 | 1997-01-14 | Herbs For Health, Inc. | Composition and method for inhibiting the desire for tobacco |
| CA2182851A1 (en) * | 1995-08-15 | 1997-02-16 | August Masaru Watanabe | Method for treating substance abuse withdrawal |
| US5795880A (en) * | 1996-12-30 | 1998-08-18 | Louisiana State University Medical Center Foundation | Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
| US5760049A (en) * | 1997-02-21 | 1998-06-02 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
| US6166032A (en) * | 1997-02-07 | 2000-12-26 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
| US6045825A (en) * | 1998-06-17 | 2000-04-04 | M. E. Cody Products, Inc. | Plantago major and Piper methysticum compound for use in treating a tobacco or nicotine habit |
| US6617361B2 (en) | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| US6333357B1 (en) * | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
| US7998217B1 (en) | 2005-02-02 | 2011-08-16 | Biomet Manufacturing Corp. | Modular offset stem implants |
| US7879913B2 (en) * | 2005-06-28 | 2011-02-01 | Catholic Healthcare West | Iptakalim hydrochloride for decreasing nicotine use |
| US7842093B2 (en) * | 2006-07-18 | 2010-11-30 | Biomet Manufacturing Corp. | Method and apparatus for a knee implant |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3146240A (en) * | 1960-03-11 | 1964-08-25 | Us Rubber Co | 2-p-anilinophenylaminoimidazoline and its salts |
| US3236857A (en) * | 1961-10-09 | 1966-02-22 | Boehringer Sohn Ingelheim | 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products |
| BE759125A (fr) * | 1969-11-19 | 1971-05-18 | Boehringer Sohn Ingelheim | Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer |
| US3850926A (en) * | 1971-01-21 | 1974-11-26 | Boehringer Sohn Ingelheim | 2-(n-substituted-phenylamino)-imidazolines-(2) |
| DE2523103C3 (de) * | 1975-05-24 | 1979-11-29 | C.H. Boehringer Sohn, 6507 Ingelheim | Substituierte 2-[N-Progargyl-N-(2-chlorphenyl)amino] -imidazoline-^), deren Säureadditionssalze, Verfahren zu ihrer Herstellung und deren Verwendung |
| DE2636732A1 (de) * | 1976-08-14 | 1978-02-16 | Boehringer Sohn Ingelheim | Neue substituierte 2-phenylamino- imidazoline- (2), deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben |
-
1979
- 1979-07-13 US US06/057,288 patent/US4255439A/en not_active Expired - Lifetime
-
1980
- 1980-06-24 DE DE3023588A patent/DE3023588C2/de not_active Expired - Fee Related
- 1980-06-25 FR FR8014153A patent/FR2460670A1/fr active Granted
- 1980-07-08 CA CA000355682A patent/CA1152003A/en not_active Expired
- 1980-07-11 GB GB8022783A patent/GB2056277B/en not_active Expired
- 1980-07-11 IT IT23411/80A patent/IT1149239B/it active
- 1980-07-14 JP JP9516980A patent/JPS5618921A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE3023588A1 (de) | 1981-01-29 |
| GB2056277B (en) | 1983-04-27 |
| JPS5618921A (en) | 1981-02-23 |
| GB2056277A (en) | 1981-03-18 |
| FR2460670B3 (index.php) | 1983-04-15 |
| FR2460670A1 (fr) | 1981-01-30 |
| US4255439A (en) | 1981-03-10 |
| IT8023411A0 (it) | 1980-07-11 |
| CA1152003A (en) | 1983-08-16 |
| IT1149239B (it) | 1986-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3023588C2 (de) | Verwendung von Clonidin oder dessen Hydrochlorid zusammen mit Phentermin zum Abgewöhnen des Rauchens | |
| DE69811378T2 (de) | Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion | |
| DE2856393C2 (de) | Arzneimittel zur Behandlung von Morbus Parkinson | |
| DE69934305T2 (de) | Verwendung von dexmedetomidine zur sedierung auf der intensivstation | |
| DE69926804T2 (de) | Vorrichtungen zur behandlung und diagnose des restless leg syndroms | |
| DE69803773T2 (de) | Yohimbine und arginin enthaltende zusammensetzung zur behandlung der erektilen fehlfunktion | |
| DE60017147T2 (de) | Verwendung von gabab-rezeptor agonisten und deren pharmazeutisch akzeptierbaren derivate bei der therapie zur erhaltung von nikotinabstinenz bei nikotinabhängigen patienten | |
| DE3116860C2 (index.php) | ||
| EP1513533A2 (de) | Pharmazeutische wirkstoffkombination sowie deren verwendung | |
| DE60015098T2 (de) | 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5-dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose | |
| Lemere et al. | Deanol (deaner) a new cerebral stimulant for the treatment of neurasthenia and mild depression: a preliminary report | |
| DE2932747A1 (de) | Arzneimittel zur behandlung von auf dopaminmangel beruhenden erkrankungen des zentralnervensystems | |
| DE19941217A1 (de) | Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben | |
| DE60108947T2 (de) | Eindämmung der wiederaufnahme von drogenmissbrauch | |
| DE60100431T2 (de) | Arzneistoffkombination zur behandlung von kopfschmerzen mit mirtazapine und paracetamol oder nicht-steroiden entzündungshemmenden mitteln | |
| EP1408968B1 (de) | Rezeptoradaptierter nikotinentzug durch eine kombination von atropin, scopolamin, clonidin | |
| DE69838875T2 (de) | Verwendung von mecamylamine zur behandlung von neuropsychiatrischen krankheiten die auf nicotin ansprechen | |
| DE1617336C2 (de) | Arzneimittel gegen Angina pectoris | |
| EP4349333B1 (de) | Verwendung von aminopyridin, insbesondere amifampridin, bei der behandlung einer viral assoziierten fatigue | |
| DE2352618A1 (de) | Arzneimittel zur behandlung des parkinsonismus | |
| DE69701139T2 (de) | Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität | |
| Kuhn et al. | Pharmacology and hypnogenic properties of brotizolam in animals. | |
| DE2513521A1 (de) | Neue zusammensetzungen zur bekaempfung von giftstoffbedingten schaedlichen wirkungen und gewoehnungserscheinungen beim menschen | |
| DE2821311A1 (de) | Arzneimittel enthaltend fusarsaeure | |
| DE2349157C3 (de) | Codeinhaltiges Hustenmittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8125 | Change of the main classification |
Ipc: A61K 31/415 |
|
| 8127 | New person/name/address of the applicant |
Owner name: BOEHRINGER INGELHEIM KG, 6507 INGELHEIM, DE |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |